| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 | Mar, 2008 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -61,410 | -36,910 | -28,290 | -20,810 | 0 |
| Net Income Growth | -66.38% | -30.47% | -35.94% | unch | unch |
Checkmate Pharmaceuticals Inc (CMPI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Checkmate Pharmaceuticals Inc. is a clinical stage biotechnology company. It is focused on developing proprietary technology to harness the power of the immune system to combat cancer. The company's product candidate includes CMP-001, which is in clinical stage. Checkmate Pharmaceuticals Inc. is based in Cambridge, United States.
Fiscal Year End Date: 12/31